BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 9989628)

  • 1. Interferon-gamma secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon-beta therapy.
    Becher B; Giacomini PS; Pelletier D; McCrea E; Prat A; Antel JP
    Ann Neurol; 1999 Feb; 45(2):247-50. PubMed ID: 9989628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent cytokine deviation toward the Th2 side in Japanese multiple sclerosis patients with interferon beta-1b.
    Ochi H; Feng-Jun M; Osoegawa M; Minohara M; Murai H; Taniwaki T; Kira J
    J Neurol Sci; 2004 Jul; 222(1-2):65-73. PubMed ID: 15240198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term favorable response to interferon beta-1b is linked to cytokine deviation toward the Th2 and Tc2 sides in Japanese patients with multiple sclerosis.
    Mei FJ; Osoegawa M; Ochi H; Minohara M; Nan S; Murai H; Ishizu T; Taniwaki T; Kira J
    J Neurol Sci; 2006 Jul; 246(1-2):71-7. PubMed ID: 16581087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [T-cell interferon-gamma, tumor necrosis factor-alpha and interleukin-6 receptor binding in patients with multiple sclerosis. Effects of interferon-beta-1b treatment].
    Bongioanni P; Romano MR; Boccardi B; Lombardo F; Moscato G; Mosti S; Baldini C; Nuti S; Meucci G; Rossi B
    Rev Neurol; 1999 Nov 16-30; 29(10):893-9. PubMed ID: 10637835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
    Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
    Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peripheral blood CD4+ T lymphocytes from multiple sclerosis patients are characterized by higher PSGL-1 expression and transmigration capacity across a human blood-brain barrier-derived endothelial cell line.
    Bahbouhi B; Berthelot L; Pettré S; Michel L; Wiertlewski S; Weksler B; Romero IA; Miller F; Couraud PO; Brouard S; Laplaud DA; Soulillou JP
    J Leukoc Biol; 2009 Nov; 86(5):1049-63. PubMed ID: 19696154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
    Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-beta regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis.
    Hamamcioglu K; Reder AT
    Mult Scler; 2007 May; 13(4):459-70. PubMed ID: 17463069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in lymphocyte subsets s and treatment with beta interferon in active multiple sclerosis].
    Gata JM; García-Moreno JM; Dinca L; Sánchez-Margalet V; Navarro G; Izquierdo G
    Rev Neurol; 1998 Dec; 27(160):939-42. PubMed ID: 9951008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
    Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
    J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymic output and peripheral T lymphocyte subsets in relapsing--remitting multiple sclerosis patients treated or not by IFN-beta.
    Puissant-Lubrano B; Viala F; Winterton P; Abbal M; Clanet M; Blancher A
    J Neuroimmunol; 2008 Jan; 193(1-2):188-94. PubMed ID: 18068811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with type I interferons induces a regulatory T cell subset in peripheral blood mononuclear cells from multiple sclerosis patients.
    Pentón-Rol G; Cervantes-Llanos M; Cabrera-Gómez JA; Alonso-Ramírez R; Valenzuela-Silva C; Rodríguez-Lara R; Montero-Casimiro E; Bello-Rivero I; López-Saura P
    Int Immunopharmacol; 2008 Jun; 8(6):881-6. PubMed ID: 18442793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective production of anti-inflammatory cytokine, TGF-beta by T cell lines of patients with active multiple sclerosis.
    Mokhtarian F; Shi Y; Shirazian D; Morgante L; Miller A; Grob D
    J Immunol; 1994 Jun; 152(12):6003-10. PubMed ID: 8207225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between peripheral IFN-gamma producing CD8+ T-cells and disability score in relapsing-remitting multiple sclerosis.
    Sepulcre J; Sanchez-Ibarrola A; Moreno C; de Castro P
    Cytokine; 2005 Oct; 32(2):111-6. PubMed ID: 16246570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma and interleukin-4-producing T cells in peripheral blood of multiple sclerosis patients.
    Franciotta D; Zardini E; Bergamaschi R; Andreoni L; Cosi V
    Eur Cytokine Netw; 2000 Dec; 11(4):677-81. PubMed ID: 11125313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
    Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis.
    Zafranskaya M; Oschmann P; Engel R; Weishaupt A; van Noort JM; Jomaa H; Eberl M
    Immunology; 2007 May; 121(1):29-39. PubMed ID: 17239199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of interferon gamma on T lymphocytes from patients with multiple sclerosis.
    Grimaldi LM; Martino G
    Mult Scler; 1995; 1 Suppl 1():S38-43. PubMed ID: 9345397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis.
    Mehling M; Brinkmann V; Antel J; Bar-Or A; Goebels N; Vedrine C; Kristofic C; Kuhle J; Lindberg RL; Kappos L
    Neurology; 2008 Oct; 71(16):1261-7. PubMed ID: 18852441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.